Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Int J Health Econ Manag. 2020 Apr 30;20(3):299–317. doi: 10.1007/s10754-020-09282-2

Figure I: Adjusted use of fenofibrates and dronedarone before and after new evidence.

Figure I:

Figure I:

Panel A: Adjusted use of fenofibrates, 2008–2013

Panel B: Adjusted use of dronedarone, 2009–2013

Notes: Estimates represent fitted values from multivariate regression models that adjust for patient race/ethnicity, SES, rurality, age, sex, and Charlson comorbidity index, and for provider age, sex, and specialty. The vertical lines indicate when the de-adoption evidence was introduced (April 2010 for fenofibrates and November 2011 for dronedarone).